ArticleBMJ open2025
Temporal trends of myocarditis burden in the Western Pacific Region from 1990 to 2021 and forecasts to 2035: a systematic analysis of data from the Global Burden of Disease Study 2021.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to analyse the burden of myocarditis in the Western Pacific Region (WPR). DESIGN AND
settingData from the Global Burden of Disease (GBD) Study 2021, covering 31 countries in the WPR, were analysed.
participantsPatients diagnosed with myocarditis. OUTCOME MEASURES: Numbers and age-standardised rates (ASRs) of incidence, prevalence, mortality and disability-adjusted life years (DALYs), along with their average annual percentage changes (AAPCs), were included. The contributions of population growth, ageing and epidemiological changes to ASR changes were assessed. Additionally, the ASRs of four indicators are projected until 2035.
resultsIn 2021, GBD estimates for myocarditis were 375 241.19 incident cases, 15 307.52 deaths and 379 674.28 DALYs in the WPR. From 1990 to 2021, the incidence, prevalence and mortality increased by 53.58%, 67.88% and 67.16%, respectively, whereas DALYs decreased by 24.77%. ASRs declined across all metrics: incidence (17.68 to 16.70 per 100,000; AAPC = -0.18, 95% CI -0.19 to -0.18), mortality (0.82 to 0.64 per 100,000; AAPC = -0.78, 95% CI -0.83 to -0.72) and DALYs (35.69 to 19.36 per 100,000; AAPC = -1.97, 95% CI -2.02 to -1.89). Papua New Guinea exhibited the highest increases in incidence, prevalence, deaths and DALYs. Japan, Singapore, China and Kiribati had the highest age-standardised incidence rate (ASIR), prevalence rate (ASPR), mortality rate (ASMR) and DALY rate (ASDR), respectively. Individuals aged ≥65 years and infants had significantly higher ASIR, ASMR and ASDR. Males consistently demonstrated higher myocarditis ASRs than females in the WPR from 1990 to 2021. Ageing was identified as the primary driver of increased incidence and mortality. Projections indicate that the ASIR of myocarditis will remain stable through 2035.
conclusionThe burden of myocarditis in the WPR exhibits substantial cross-country variation, with males, infants and the elderly disproportionately affected, underscoring the urgent need for context-specific management strategies tailored to high-risk populations and regional epidemiological profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.